Actively Recruiting
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Led by Samsung Medical Center · Updated on 2025-06-29
400
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery. The main questions it aims to answer are: * 7-year ipsilateral breast tumor recurrence * 7-year disease-free survival * 7-year locoregional recurrence * 7-year overall survival * Adverse events of radiation therapy Participants will be assessed by multi-dimensional methods after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0
CONDITIONS
Official Title
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 19 years or older
- Pathological confirmation of HER2 positive invasive breast cancer
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Informed consent provided by the participant
You will not qualify if you...
- Pathological confirmation of ductal carcinoma in situ of the breast
- Previous history of radiation therapy to the ipsilateral breast
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
H
Haeyoung Kim, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here